199113-98-9
199113-98-9 结构式
基本信息
Drf-2593
Drf 2593
Balaglitazone
Unii-4m1609828o
Balaglitazone [inn]
DRF-2593
NN-2344
DRF2593
NN2344
DRF 2593
NN 2344
(+/-)-5-(p-((3,4-Dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy)benzyl)-2,4-thiazolidinedione
5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-2,4-Thiazolidinedione
5-[[4-[[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl]methyl]thiazolidine-2,4-dione
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-16086 | 巴格列酮 Balaglitazone | 199113-98-9 | 5mg | 1900元 |
| 2024/04/30 | HY-16086 | 巴格列酮 Balaglitazone | 199113-98-9 | 10mM * 1mLin DMSO | 2090元 |
| 2024/04/30 | HY-16086 | 巴格列酮 Balaglitazone | 199113-98-9 | 50mg | 7812元 |
常见问题列表
|
PPARγ 351 nM (EC 50 , Human PPARγ) |
Balaglitazone is a selective partial PPARγ agonist with an EC 50 of 1.351 μM. Balaglitazone (5-100 μM) has equal cytotoxicity towards K562 and K562/DOX cells. Balaglitazone decreases doxorubicin cytotoxicity in K562 and K562/DOX cells, with IC 50 s of 0.117 μM and 0.53 μM, respectively. Balaglitazone reverses multidrug resistance (MDR) in K562/DOX cells. Balaglitazone (25 µM) increases Rh123 accumulation in K562/DOX cells, but does not increases MFI in K562 cells. Balaglitazone downregulates P-gp expression in K562/DOX cells, and such effects are via upregulation of PTEN in K562/DOX cells, and be abolished by PTEN inhibition.
Balaglitazone (3 mg/kg, p.o.) shows antihyperglycaemic activity in fully diabetic and insulin resistant db/db mice, and is more potent than the full PPARγ agonist rosiglitazone. Balaglitazone (10 mg/kg, p.o.) suppresses overall glucose, decreases insulin levels, and increases bodyweight in male diet-induced obese rats, and such effects are equal to that of 30 mg/kg pioglitazone.